Literature DB >> 15099931

Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats.

Kimmo Ingman1, Jukka Sallinen, Aapo Honkanen, Esa R Korpi.   

Abstract

Interactions between alcohol and traditional benzodiazepine anxiolytics hamper the treatment of alcoholism-related anxiety disorders. Serotonin 5-HT(2) receptor antagonists, such as deramciclane, are anxiolytic, and considering their pharmacological profile, they might benefit alcoholics with comorbid anxiety. We studied the effects of acute deramciclane (1, 3 and 10 mg/kg i.p.) on alcohol drinking of alcohol-preferring AA rats drinking 10% (vol/vol) ethanol solution in a 4-h limited-access paradigm. Thereafter, a 5-day repeated-treatment experiment was carried out, under corresponding test design, with deramciclane (3 mg/kg i.p.) as a test drug and midazolam (1 mg/kg i.p.) as a benzodiazepine reference compound. Deramciclane had no effect on alcohol consumption in either acute or repeated dosing study. Midazolam increased ethanol drinking, as expected, when administered on successive days. A modified functional observational battery (FOB) procedure was applied to study neurological, behavioural and autonomic effects induced by deramciclane (1-30 mg/kg po) and diazepam (1-30 mg/kg po) in mice at 30 min, 2 h and 4 h after dosing. Deramciclane had a mild dopamine D(2) receptor antagonism-like effect at the highest dose. The effects of diazepam were predictable, myorelaxation-induced motor impairment and anxiolysis-related hyperlocomotion in a novel environment being the characteristic features at the two highest doses. Deramciclane appears to be a safe and well-tolerated drug and we suggest that it might be useful in the treatment of anxiety in alcoholics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099931     DOI: 10.1016/j.pbb.2004.02.015

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  5 in total

Review 1.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

2.  GABAA receptor regulation of voluntary ethanol drinking requires PKCepsilon.

Authors:  Joyce Besheer; Veronique Lepoutre; Beth Mole; Clyde W Hodge
Journal:  Synapse       Date:  2006-11       Impact factor: 2.562

Review 3.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

4.  Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects.

Authors:  Helga Höifödt Lidö; Susanne Jonsson; Petri Hyytiä; Mia Ericson; Bo Söderpalm
Journal:  J Neural Transm (Vienna)       Date:  2017-02-04       Impact factor: 3.575

5.  A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects.

Authors:  Thomas Ricketts; Philip McGoldrick; Pietro Fratta; Hugo M de Oliveira; Rosie Kent; Vinaya Phatak; Sebastian Brandner; Gonzalo Blanco; Linda Greensmith; Abraham Acevedo-Arozena; Elizabeth M C Fisher
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.